search
Back to results

Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth (MONS)

Primary Purpose

Faltering Growth

Status
Recruiting
Phase
Not Applicable
Locations
Malaysia
Study Type
Interventional
Intervention
Milnutri Sure™
Sponsored by
Danone Specialized Nutrition (M) Sdn Bhd
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Faltering Growth

Eligibility Criteria

1 Year - 6 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age: ≥1 and ≤ 6 years of age.
  2. Weight at baseline between ≥ -3 and < -1 SD WHO-score (mild to moderate undernutrition).
  3. Informed consent provided.

Exclusion Criteria:

  1. Underlying medical illness affecting growth, according to the clinician's opinion
  2. Known lactose intolerance / cow's milk allergy
  3. Use of (other) ONS 1+ (1 kcal/mL) at enrolment and/or during the three months before enrolment
  4. Other family member is already participating in this MONS study.
  5. Insufficient ability to understand or communicate in English and/or Bahasa Malaysia
  6. Participating in any other clinical study

Sites / Locations

  • Hospital Pengajar Universiti Putra MalaysiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Treatment

Control

Arm Description

The subjects in the treatment arm will be given Milnutri Sure TM product with dietary counselling

The subjects in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.

Outcomes

Primary Outcome Measures

Weight for Age (WAZ) score of the subject
derived from weight and age

Secondary Outcome Measures

Weight for Height (WHZ) score, weight and height of the subject
derived from height and weight
(Serious) Adverse Events of the IP and possible relatedness to study
Number, type and severity of (Serious) Adverse Events and possible relatedness to study product
Percentage of compliance
Percentage of compliance via missed servings compared to expected servings on product intake
Appetite score
Appetite score according to a visual analogue scale (0-10)
Nutritional intake
Total energy intake and nutrient intake from solid food

Full Information

First Posted
January 3, 2022
Last Updated
August 22, 2022
Sponsor
Danone Specialized Nutrition (M) Sdn Bhd
Collaborators
Universiti Putra Malaysia
search

1. Study Identification

Unique Protocol Identification Number
NCT05193630
Brief Title
Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth
Acronym
MONS
Official Title
A Randomised, Open Label, Controlled Intervention Study to Investigate the Effects Oral Nutritional Supplement in Malaysian Children With Faltering Growth
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
July 7, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
August 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Danone Specialized Nutrition (M) Sdn Bhd
Collaborators
Universiti Putra Malaysia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A randomised, open label, controlled intervention study to test the effect of the test product with dietary counselling versus dietary counselling alone on Weight-for-Age z-score change in children from ≥ 1 to ≤ 6 years of age with faltering growth for duration of 12 weeks.
Detailed Description
Parent(s) of potentially eligible subjects will be informed about the study and what is expected in case of participation to the study. Information on the study is incorporated in the Respondent's Information Sheet (RIS). The parent(s) will be given sufficient time to read and understand the Information Sheet and to ask questions. Parent(s) of eligible subjects will be approached at the main study clinic or they may be referred from one of the 'satellite clinics'. In case of referral, they will be pre-screened at the satellite clinic and if considered potentially eligible for the MONS study, they will be referred to the main study clinic for full screening. If subjects fulfil all inclusion and exclusion criteria, and if the parent(s) is (are) willing that his/her/their child will participate, he/she/they will be asked to sign the Informed Consent Form (ICF). Baseline evaluation (including history and anthropometric measurement) will be completed prior to randomisation. A block randomisation will be performed to allocate subjects to treatment arm or control arm in 1:1 ratio. At enrolment, the investigator assesses baseline characteristics, anthropometrics, appetite score, and the number of the child's sick days during the 4 weeks before enrolment. At the end of the visit, the investigator will provide two 3-days feeding diaries (one for baseline and one for Visit 2) and explain how and when these should be completed. The investigator will provide the Milnutri Sure™ product to the parent whose child is in the treatment arm, explain how to use the Milnutri Sure™ and how to apply other feeding advices for the coming 4 weeks until the next visit. For parent whose child is in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator. Four, eight and twelve weeks after enrolment, subjects will have clinic visits (Visit 2, 3 and 4) and the anthropometrics, adverse events, appetite score, compliance, and the number of the children's sick days since last visit will be assessed. At the end of the visit the investigator will provide the product to the parents whose children are in the treatment arm, explains how to use it and how to apply other feeding advices for the coming 4 weeks until the next visit. For parents whose children are in the control arm, though no Milnutri Sure TM product will be given, dietary counselling will be provided by the investigator. At week eight (Visit 3), the investigator will also provide a 3-days feeding diary to the parents to be completed just before the twelve-week 12 visit (Visit 4). In addition to this, at Visit 4 (the End of Study visit after 12 weeks in the study) the investigator will fill out the end of study visit requirements and stops providing study product. The investigator may request for a follow-up visit to monitor and provide medical and dietary counselling to the subject. If necessary, the investigator may prescribe Milnutri Sure ™ or any other growing up milk or nutritional counselling as part of normal practice.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Faltering Growth

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
A randomised, open label, controlled intervention study
Masking
Outcomes Assessor
Masking Description
The anthropometric outcomes will be blinded to assessors and analyst until at least the primary outcomes have been analysed to reduce bias.
Allocation
Randomized
Enrollment
172 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Experimental
Arm Description
The subjects in the treatment arm will be given Milnutri Sure TM product with dietary counselling
Arm Title
Control
Arm Type
Active Comparator
Arm Description
The subjects in the control arm, no Milnutri Sure TM product will be given, nevertheless, dietary counselling will be provided by the investigator.
Intervention Type
Dietary Supplement
Intervention Name(s)
Milnutri Sure™
Other Intervention Name(s)
oral nutritional support (ONS) product in powder format
Intervention Description
Milnutri Sure™, a commercially available oral nutritional support (ONS) product in powder format, for children of 1 y of age and above (1.0 kcal /ml). For children between 1 and 3 years of age, the recommendation is to use 2 servings per day, and for children from 4 to 6 years of age, the recommendation is to give 3 servings per day. One serving contains of 45 grams of product and 180 ml water.
Primary Outcome Measure Information:
Title
Weight for Age (WAZ) score of the subject
Description
derived from weight and age
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Weight for Height (WHZ) score, weight and height of the subject
Description
derived from height and weight
Time Frame
12 weeks
Title
(Serious) Adverse Events of the IP and possible relatedness to study
Description
Number, type and severity of (Serious) Adverse Events and possible relatedness to study product
Time Frame
12 weeks
Title
Percentage of compliance
Description
Percentage of compliance via missed servings compared to expected servings on product intake
Time Frame
12 weeks
Title
Appetite score
Description
Appetite score according to a visual analogue scale (0-10)
Time Frame
12 weeks
Title
Nutritional intake
Description
Total energy intake and nutrient intake from solid food
Time Frame
12 weeks
Other Pre-specified Outcome Measures:
Title
Number of sick days
Description
Number of sick days assessed via the investigator, who, at each clinic visit, asks the parents for the number of sick days during the past 4 weeks.
Time Frame
12 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
6 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: ≥1 and ≤ 6 years of age. Weight at baseline between ≥ -3 and < -1 SD WHO-score (mild to moderate undernutrition). Informed consent provided. Exclusion Criteria: Underlying medical illness affecting growth, according to the clinician's opinion Known lactose intolerance / cow's milk allergy Use of (other) ONS 1+ (1 kcal/mL) at enrolment and/or during the three months before enrolment Other family member is already participating in this MONS study. Insufficient ability to understand or communicate in English and/or Bahasa Malaysia Participating in any other clinical study
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Zurina Zainudin
Phone
+6012-2642174
Email
zaizurina@upm.edu.my
First Name & Middle Initial & Last Name or Official Title & Degree
Diana Rashid
Phone
+6013-4619940
Email
diana.rashid@questra.com.my
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zurina Zainudin
Organizational Affiliation
Universiti Putra Malaysia
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Pengajar Universiti Putra Malaysia
City
Serdang
State/Province
Selangor Darul Ehsan
ZIP/Postal Code
43400
Country
Malaysia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
ZURINA ZAINUDDIN

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intervention Study to Investigate the Effects of ONS Use Among Malaysian Children With Faltering Growth

We'll reach out to this number within 24 hrs